Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Hepatitis D Market from 2024 to 2025?
There has been a sustained growth in the hepatitis D market size in the past few years. It is projected to escalate from $0.72 billion in 2024 to $0.76 billion in 2025, marking a compound annual growth rate (CAGR) of 4.6%. The expansion experienced in the historical period is due to factors such as the scarcity of treatment alternatives, high incidence in areas where the disease is endemic, simultaneous infection with hepatitis B, low levels of awareness and diagnosis, and governmental immunization initiatives.
What Is the Projected Market Size of the Hepatitis D Market?
The market for hepatitis D is projected to witness consistent expansion in the coming years, reaching a valuation of $0.90 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 4.4%. Factors contributing to growth during the forecast period include wider reimbursement provisions for new treatment methods, growing investments in the health sector, increased use of combination therapies, an upturn in hepatitis B immunization coverage, and the growth of public health programs. The forecast period will also see key trends such as progress in molecular diagnostic instruments, a move towards personalized medicine for dealing with liver diseases, the creation of innovative RNA-based treatments, the expansion of clinical trials for hepatitis D remedies, and the embrace of telemedicine in managing hepatitis.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp
Who are the Major Competitors in the Hepatitis D Market Outlook?
Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, Biorex Diagnostics Ltd.
What Is Fueling Growth in the Hepatitis D Market?
The escalating occurrences of hepatitis B is anticipated to boost the expansion of the hepatitis D market in the future. Hepatitis B, a viral infection that impacts the liver and causes symptoms like jaundice, tiredness, and abdominal discomfort, could result in chronic liver illness or liver cancer if not addressed promptly. The upsurge in Hepatitis B instances is linked to certain risk behaviors such as unprotected sex, needle sharing, transmission from mother to child during childbirth, and inadequate vaccination coverage in certain areas. Hepatitis D depends on the Hepatitis B virus for replication, making use of Hepatitis B’s surface antigen to infect liver cells, emphasizing the crucial nature of dual infection in liver disease progression. For example, the Department of Health and Human Services, a US-based government department, reported in November 2023 that new chronic hepatitis B cases increased 11% in 2022 compared to 2021. Consequently, the rising prevalence of hepatitis B propels the expansion of the hepatitis D market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21202&type=smp
Which Hepatitis D Market Segments Are Growing the Fastest?
The hepatitis d market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online Pharmacies
4) By End-Users: Clinic, Hospital, Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D
Which Industry Trends Are Shaping the Future of the Hepatitis D Market?
In the Hepatitis D market, leading companies are prioritizing the creation of groundbreaking formulations such as recombinant vaccines. These new vaccines aim to improve immunization effectiveness and deliver prolonged defense against the virus. Recombinant vaccines are created by incorporating a gene encoding a viral protein into a host organism like bacteria or yeast. The subsequent protein production is then used to elicit an immune response, without triggering the associated disease. An example of this occurred in December 2022, when Health Canada approved PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)] developed by VBI Vaccines Inc., a biotech company based in the US. This vaccine actively immunizes against all recognized hepatitis B subtypes in adults 18 years and older, effectively extending its prevention to hepatitis D. This is because hepatitis D, caused by the delta agent, can’t emerge without a preexisting hepatitis B infection. The vaccine’s approval was facilitated by positive outcomes from two critical Phase 3 clinical trials, protect and constant. These studies showed that PreHevbrio offered higher seroprotection rates when juxtaposed with the single-antigen Engerix-B vaccine.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
Which Countries Are Leading the Hepatitis D Market?
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21202
This Report Delivers Insight On:
1. How big is the hepatitis d market, and how is it changing globally?
2. Who are the major companies in the hepatitis d market, and how are they performing?
3. What are the key opportunities and risks in the hepatitis d market right now?
4. Which products or customer segments are growing the most in the hepatitis d market?
5. What factors are helping or slowing down the growth of the hepatitis d market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model